Home-Based Up-Dosing in Build-Up Phase of Oral Immunotherapy of Egg Allergy Is Safe and Feasible in Real-World Practice

Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the...

Full description

Saved in:
Bibliographic Details
Published inAllergy, asthma & immunology research Vol. 13; no. 5; pp. 791 - 798
Main Authors Jeong, Hye-In, Lee, Bora, Kim, Sukyung, Kyung, Yechan, Jung, Minyoung, Kim, Minji, Lee, Ji Young, Kim, Kevin, Ahn, Kangmo, Kim, Jihyun
Format Journal Article
LanguageEnglish
Published Seoul Korean Academy of Asthma, Allergy and Clinical Immunology 01.09.2021
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
대한천식알레르기학회
Subjects
Online AccessGet full text
ISSN2092-7355
2092-7363
DOI10.4168/aair.2021.13.5.791

Cover

Abstract Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy.
AbstractList Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy.Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy.
Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period ( P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy.
Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy. KCI Citation Count: 1
Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase compliance and ensure safety because OIT requires an extended period of time and has a risk of side effects like anaphylaxis. We aimed to show the feasibility and safety of OIT during the build-up phase using a home-based, up-dosing method in children with egg allergy. Sixteen patients aged 4 to 12 years with egg allergy were enrolled. Patients increased the dose of boiled egg white (EW) by 5% per day at home and 25% per month at the hospital, with a target dose of 40 g of boiled EW (4.0 g of EW proteins). A historical control group (n = 16) was matched for age, sex, and clinical characteristics for comparisons with the OIT group. Oral food challenge (OFC) tests were performed after completing the build-up phase. In the OIT group, 93.8% (15/16) of patients achieved desensitization, with only 1 patient discontinuing OIT before the maintenance phase due to repeated allergic reactions. Mild allergic reactions and anaphylaxis occurred in 12 (75.0%) and 2 patients (12.5%), respectively. However, there were no significant adverse reactions such as serious anxiety or life-threatening events that required discontinuation of treatment. On the contrary, only 1 patient (6.3%) in the control group passed an OFC of 40 g of boiled EW during the same period (P < 0.001). Our results suggest that home-based up-dosing protocols using boiled eggs may be safe and feasible for the build-up phase of OIT in children with egg allergy.
Author Jung, Minyoung
Kim, Jihyun
Kim, Sukyung
Lee, Bora
Jeong, Hye-In
Lee, Ji Young
Ahn, Kangmo
Kyung, Yechan
Kim, Kevin
Kim, Minji
AuthorAffiliation 6 Department of Pediatrics, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea
1 Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
4 Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
5 Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Korea
7 School of Arts and Sciences, University of Richmond, Richmond, VA, USA
2 Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea
3 Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
AuthorAffiliation_xml – name: 6 Department of Pediatrics, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea
– name: 3 Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
– name: 7 School of Arts and Sciences, University of Richmond, Richmond, VA, USA
– name: 2 Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea
– name: 5 Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Korea
– name: 1 Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
– name: 4 Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
Author_xml – sequence: 1
  givenname: Hye-In
  orcidid: 0000-0001-8843-0651
  surname: Jeong
  fullname: Jeong, Hye-In
  organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea
– sequence: 2
  givenname: Bora
  orcidid: 0000-0002-7718-1159
  surname: Lee
  fullname: Lee, Bora
  organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea
– sequence: 3
  givenname: Sukyung
  orcidid: 0000-0002-3204-1398
  surname: Kim
  fullname: Kim, Sukyung
  organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea
– sequence: 4
  givenname: Yechan
  orcidid: 0000-0002-4982-863X
  surname: Kyung
  fullname: Kyung, Yechan
  organization: Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
– sequence: 5
  givenname: Minyoung
  orcidid: 0000-0003-2851-9480
  surname: Jung
  fullname: Jung, Minyoung
  organization: Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
– sequence: 6
  givenname: Minji
  orcidid: 0000-0001-5588-5414
  surname: Kim
  fullname: Kim, Minji
  organization: Department of Pediatrics, Chungnam National University Sejong Hospital, Sejong, Korea
– sequence: 7
  givenname: Ji Young
  orcidid: 0000-0002-2260-9939
  surname: Lee
  fullname: Lee, Ji Young
  organization: Department of Pediatrics, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea
– sequence: 8
  givenname: Kevin
  orcidid: 0000-0002-0220-1848
  surname: Kim
  fullname: Kim, Kevin
  organization: School of Arts and Sciences, University of Richmond, Richmond, VA, USA
– sequence: 9
  givenname: Kangmo
  orcidid: 0000-0001-7751-9829
  surname: Ahn
  fullname: Ahn, Kangmo
  organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea
– sequence: 10
  givenname: Jihyun
  orcidid: 0000-0001-8493-2881
  surname: Kim
  fullname: Kim, Jihyun
  organization: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea
BackLink https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002751768$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kkFP3DAQhaOKqlDKH-jJUi_tIdvYsZ34UmmhUFZCAlFWPVqzyWTX4NiLnbTaf1-HRUjlUF9seb73NGO_99mB8w6z7CMtZpzK-iuACTNWMDqj5UzMKkXfZEesUCyvSlkevJyFOMxOYrwv0iop55K_yw5LzmvJJDvK_lz6HvNTiNiS5Tb_7qNxa2IcOR2NbfPlltxsUpH4jlwHsGTR96PzwwYDbHfT7fl6TebWYljvyCKSn9AhAdeSC4RoVhYnr1sEm__ywbbkJkAzmAY_ZG87sBFPnvfjbHlxfnd2mV9d_1icza_yhnM65I1iVckZq7qi45VoVwi0Q1CSYV0qKiUILCUFBjUViikAUTRYVKrtWtHWWB5nX_a-LnT6oTHag3na114_BD2_vVtoVYsqaRP7bc9ux1WPbYNuSCPrbTA9hN2T8t-KM5vk81vXnCrJ62Tw-dkg-McR46B7Exu0Fhz6MWompJK0Sr-Q0E-v0Hs_BpeeIlFVGphXNU0U21NN8DEG7F6aoYWeYqCnGOgpBpqWWugUgySqX4kaM8Bg_NS0sf-T_gWaP7fe
CitedBy_id crossref_primary_10_1007_s11882_024_01191_5
crossref_primary_10_1111_cea_70013
crossref_primary_10_2500_aap_2024_45_240001
crossref_primary_10_1016_j_mcna_2023_08_011
crossref_primary_10_1111_pai_14216
crossref_primary_10_1111_pai_14003
crossref_primary_10_3345_cep_2023_01123
crossref_primary_10_1016_j_pop_2022_11_006
crossref_primary_10_3345_cep_2023_00234
crossref_primary_10_2174_1389203723666220603155320
crossref_primary_10_4168_aard_2023_11_2_93
crossref_primary_10_1016_j_jaip_2024_09_025
Cites_doi 10.1016/j.jaci.2005.12.1303
10.1111/j.1399-3038.2012.01349.x
10.1016/j.jaci.2018.08.041
10.1016/j.jaci.2010.11.044
10.4168/aair.2013.5.2.96
10.1016/j.jaci.2017.11.003
10.1016/j.jaip.2015.01.017
10.1016/j.jaip.2017.09.016
10.1016/j.jaci.2020.05.040
10.1016/j.jaci.2010.10.008
10.1111/pai.12974
10.4168/aard.2020.8.3.161
10.1111/ped.13210
10.4168/aair.2019.11.3.433
10.2500/ar.2017.8.0211
10.1056/NEJMoa1200435
10.4168/aair.2020.12.3.496
10.1016/j.jaci.2015.12.1316
10.4168/aair.2014.6.2.131
10.1542/peds.2011-0204
10.1016/j.anai.2016.11.023
ContentType Journal Article
Copyright Copyright Korean Academy of Asthma, Allergy and Clinical Immunology Sep 2021
Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease.
Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease
Copyright_xml – notice: Copyright Korean Academy of Asthma, Allergy and Clinical Immunology Sep 2021
– notice: Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease.
– notice: Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease
DBID AAYXX
CITATION
7T5
7U7
C1K
H94
7X8
5PM
ACYCR
DOI 10.4168/aair.2021.13.5.791
DatabaseName CrossRef
Immunology Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
AIDS and Cancer Research Abstracts
Immunology Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


AIDS and Cancer Research Abstracts
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2092-7363
EndPage 798
ExternalDocumentID oai_kci_go_kr_ARTI_9857929
PMC8419648
10_4168_aair_2021_13_5_791
GrantInformation_xml – fundername: ;
GroupedDBID ---
5-W
53G
8JR
8XY
9ZL
AAKDD
AAYXX
ACPRK
ADBBV
ADRAZ
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
C~G
DIK
DYU
E3Z
EF.
F5P
GX1
HYE
KQ8
M48
O5R
O5S
OK1
PGMZT
RPM
7T5
7U7
C1K
H94
7X8
5PM
ACYCR
M~E
OZF
ID FETCH-LOGICAL-c441t-c92734227f0f475dbea1fea962e839166a5e361a2a815929aa50ce079dfd5d8e3
IEDL.DBID M48
ISSN 2092-7355
IngestDate Tue Nov 21 21:16:37 EST 2023
Thu Aug 21 18:31:05 EDT 2025
Fri Jul 11 02:53:09 EDT 2025
Mon Jun 30 12:08:19 EDT 2025
Thu Apr 24 23:05:05 EDT 2025
Fri Jul 04 01:06:57 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
License https://creativecommons.org/licenses/by-nc/4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c441t-c92734227f0f475dbea1fea962e839166a5e361a2a815929aa50ce079dfd5d8e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-8493-2881
0000-0003-2851-9480
0000-0001-8843-0651
0000-0002-3204-1398
0000-0002-7718-1159
0000-0002-4982-863X
0000-0002-2260-9939
0000-0002-0220-1848
0000-0001-5588-5414
0000-0001-7751-9829
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.4168/aair.2021.13.5.791
PMID 34486262
PQID 2572274781
PQPubID 2048270
PageCount 8
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9857929
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8419648
proquest_miscellaneous_2569617144
proquest_journals_2572274781
crossref_primary_10_4168_aair_2021_13_5_791
crossref_citationtrail_10_4168_aair_2021_13_5_791
PublicationCentury 2000
PublicationDate 2021-09-01
PublicationDateYYYYMMDD 2021-09-01
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-01
  day: 01
PublicationDecade 2020
PublicationPlace Seoul
PublicationPlace_xml – name: Seoul
PublicationTitle Allergy, asthma & immunology research
PublicationYear 2021
Publisher Korean Academy of Asthma, Allergy and Clinical Immunology
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
대한천식알레르기학회
Publisher_xml – name: Korean Academy of Asthma, Allergy and Clinical Immunology
– name: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
– name: 대한천식알레르기학회
References Sicherer (10.4168/aair.2021.13.5.791_ref2) 2011; 127
Shin (10.4168/aair.2021.13.5.791_ref20) 2013; 5
Horino (10.4168/aair.2021.13.5.791_ref21) 2019; 11
Gupta (10.4168/aair.2021.13.5.791_ref1) 2011; 128
Sampson (10.4168/aair.2021.13.5.791_ref9) 2006; 117
Burks (10.4168/aair.2021.13.5.791_ref6) 2012; 367
Akashi (10.4168/aair.2021.13.5.791_ref17) 2017; 59
Nowak-Węgrzyn (10.4168/aair.2021.13.5.791_ref7) 2019; 143
Boyce (10.4168/aair.2021.13.5.791_ref4) 2010; 126
Kim (10.4168/aair.2021.13.5.791_ref14) 2020; 8
Bird (10.4168/aair.2021.13.5.791_ref8) 2018; 6
Meglio (10.4168/aair.2021.13.5.791_ref16) 2017; 8
Park (10.4168/aair.2021.13.5.791_ref3) 2014; 6
Lee (10.4168/aair.2021.13.5.791_ref10) 2020; 12
Caminiti (10.4168/aair.2021.13.5.791_ref15) 2015; 3
Martín-Muñoz (10.4168/aair.2021.13.5.791_ref11) 2019; 30
Pérez-Rangel (10.4168/aair.2021.13.5.791_ref12) 2017; 118
Dello Iacono (10.4168/aair.2021.13.5.791_ref13) 2013; 24
Kim (10.4168/aair.2021.13.5.791_ref19) 2020; 146
Sicherer (10.4168/aair.2021.13.5.791_ref5) 2018; 141
Jones (10.4168/aair.2021.13.5.791_ref18) 2016; 137
References_xml – volume: 117
  start-page: 391
  year: 2006
  ident: 10.4168/aair.2021.13.5.791_ref9
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2005.12.1303
– volume: 24
  start-page: 66
  year: 2013
  ident: 10.4168/aair.2021.13.5.791_ref13
  publication-title: Pediatr Allergy Immunol
  doi: 10.1111/j.1399-3038.2012.01349.x
– volume: 143
  start-page: 651
  year: 2019
  ident: 10.4168/aair.2021.13.5.791_ref7
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2018.08.041
– volume: 127
  start-page: 594
  year: 2011
  ident: 10.4168/aair.2021.13.5.791_ref2
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2010.11.044
– volume: 5
  start-page: 96
  year: 2013
  ident: 10.4168/aair.2021.13.5.791_ref20
  publication-title: Allergy Asthma Immunol Res
  doi: 10.4168/aair.2013.5.2.96
– volume: 141
  start-page: 41
  year: 2018
  ident: 10.4168/aair.2021.13.5.791_ref5
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2017.11.003
– volume: 3
  start-page: 532
  year: 2015
  ident: 10.4168/aair.2021.13.5.791_ref15
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2015.01.017
– volume: 6
  start-page: 476
  year: 2018
  ident: 10.4168/aair.2021.13.5.791_ref8
  publication-title: J Allergy Clin Immunol Pract
  doi: 10.1016/j.jaip.2017.09.016
– volume: 146
  start-page: 851
  year: 2020
  ident: 10.4168/aair.2021.13.5.791_ref19
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2020.05.040
– volume: 126
  start-page: 1105
  year: 2010
  ident: 10.4168/aair.2021.13.5.791_ref4
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2010.10.008
– volume: 30
  start-page: 81
  year: 2019
  ident: 10.4168/aair.2021.13.5.791_ref11
  publication-title: Pediatr Allergy Immunol
  doi: 10.1111/pai.12974
– volume: 8
  start-page: 161
  year: 2020
  ident: 10.4168/aair.2021.13.5.791_ref14
  publication-title: Allergy Asthma Respir Dis
  doi: 10.4168/aard.2020.8.3.161
– volume: 59
  start-page: 534
  year: 2017
  ident: 10.4168/aair.2021.13.5.791_ref17
  publication-title: Pediatr Int
  doi: 10.1111/ped.13210
– volume: 11
  start-page: 433
  year: 2019
  ident: 10.4168/aair.2021.13.5.791_ref21
  publication-title: Allergy Asthma Immunol Res
  doi: 10.4168/aair.2019.11.3.433
– volume: 8
  start-page: 157
  year: 2017
  ident: 10.4168/aair.2021.13.5.791_ref16
  publication-title: Allergy Rhinol (Providence)
  doi: 10.2500/ar.2017.8.0211
– volume: 367
  start-page: 233
  year: 2012
  ident: 10.4168/aair.2021.13.5.791_ref6
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1200435
– volume: 12
  start-page: 496
  year: 2020
  ident: 10.4168/aair.2021.13.5.791_ref10
  publication-title: Allergy Asthma Immunol Res
  doi: 10.4168/aair.2020.12.3.496
– volume: 137
  start-page: 1117
  year: 2016
  ident: 10.4168/aair.2021.13.5.791_ref18
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2015.12.1316
– volume: 6
  start-page: 131
  year: 2014
  ident: 10.4168/aair.2021.13.5.791_ref3
  publication-title: Allergy Asthma Immunol Res
  doi: 10.4168/aair.2014.6.2.131
– volume: 128
  start-page: e9
  year: 2011
  ident: 10.4168/aair.2021.13.5.791_ref1
  publication-title: Pediatrics
  doi: 10.1542/peds.2011-0204
– volume: 118
  start-page: 356
  year: 2017
  ident: 10.4168/aair.2021.13.5.791_ref12
  publication-title: Ann Allergy Asthma Immunol
  doi: 10.1016/j.anai.2016.11.023
SSID ssj0000314464
Score 2.3082829
Snippet Oral immunotherapy (OIT) has emerged to build sustained unresponsiveness or tolerance in patients with egg allergy. However, it is important to increase...
SourceID nrf
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 791
SubjectTerms Accumulation
Allergic reactions
Allergies
Anaphylaxis
Brief Communication
Children
Desensitization
Dosage
Eggs
Feasibility
Immunotherapy
Patients
Safety
Side effects
내과학
Title Home-Based Up-Dosing in Build-Up Phase of Oral Immunotherapy of Egg Allergy Is Safe and Feasible in Real-World Practice
URI https://www.proquest.com/docview/2572274781
https://www.proquest.com/docview/2569617144
https://pubmed.ncbi.nlm.nih.gov/PMC8419648
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002751768
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Allergy, 2021, Asthma & Immunology Research, 13(5), , pp.791-798
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fT9swELYYk6a9TBtsWhlDZtobcpbEdmI_TbCB6CQGYovEnizXsUtFlXSlCPrf7y5NKyIB0p6ixD8S-7N938W-O0I-K865jF0OCLjAhLaSDVTCmQIqkvrQeN3C0xY_s-NC_LiQF2tkGe6o7cDrB1U7jCdVTMfR3d_5V5jwwF8joBPqi7Uj9OyZJlHCIxnlaMz-HCRThsrYSUv3m5WZo_aDG81prIFYgqxd2NE8Uk1HVj2rpqFDQ7uHKO9JpaPX5FVLJ-n-Av83ZM1XG-TFSbthvkluMQw6OwBRVdJiwr7X-GuAjip6gOGwWTGhZ5eQSOtAT6F62kdzkdYoa45PD4dDuo_mgsM57V_TXzZ4aquSAnWEyTT2WNc5kE3WnMqhZ63R1VtSHB3-_nbM2lgLzAEhmjGn0c9NmuYhDiKX5cDbJHirATCFtrmZlZ5niU2tAgKUamsBYR_nugylLJXn78h6VVf-PaFQIIMHZSy8Be1NaZEPtBOBC5s5l-geSZa9alzriBzjYYwNKCSIhEEkDCJhEm6kASR6ZG9VZrJww_Fk7k8AlrlyI4Pes_E6rM3V1ICO0DdayRxa0CPbSyzNctgZWMBS1NMV1LG7SoYZh9sotvL1DebJdIZx40WP5J0xsPo0fGs3pRpdNr67lUAPaGrrv9rzgbzE-8XRtm2yPpve-I_AhWaDHdAC_hQ7zTD_B1GABKc
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Home-Based+Up-Dosing+in+Build-Up+Phase+of+Oral+Immunotherapy+of+Egg+Allergy+Is+Safe+and+Feasible+in+Real-World+Practice&rft.jtitle=Allergy%2C+asthma+%26+immunology+research&rft.au=Jeong%2C+Hye-In&rft.au=Lee%2C+Bora&rft.au=Kim%2C+Sukyung&rft.au=Kyung%2C+Yechan&rft.date=2021-09-01&rft.issn=2092-7355&rft.eissn=2092-7363&rft.volume=13&rft.issue=5&rft.spage=791&rft_id=info:doi/10.4168%2Faair.2021.13.5.791&rft.externalDBID=n%2Fa&rft.externalDocID=10_4168_aair_2021_13_5_791
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2092-7355&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2092-7355&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2092-7355&client=summon